提升肾移植与异种移植的作用:美国国家肾脏基金会科学研讨会报告
尽管努力增加供肾,约10万人在等待名单上且20年无下降。移植结局优于透析,但等待时间影响结局。猪-人肾异种移植正成为潜在解决方案,本报告总结2022年4月11-12日NKF会议对此的评估。
要点
- 肾移植结局优于透析,但透析等待时间影响移植后结局。
- 透析等待<6个月的 deceased-donor 受者与等待>2年的活体供肾受者移植存活率相当。
- 猪-人肾异种移植是应对供肾短缺的潜在策略。
核心结论
- 猪-人肾异种移植是应对终末期肾病供肾短缺的潜在策略,需进一步评估。
研究设计与样本
- 美国国家肾脏基金会于2022年4月11-12日召开科学研讨会,总结会议内容。
主要发现
- 约10万人在肾移植等待名单上,过去20年无显著减少。
- 2021年>12000人在等待名单上≥5年。
- 透析等待<6个月的 deceased-donor 受者与等待>2年的活体供肾受者移植存活率相当。
临床怎么用
- 肾移植优于慢性透析,但应关注透析等待时间对移植结局的影响。
- 猪-人肾异种移植作为潜在解决方案,需进一步临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease affects an estimated 37 million people in the United States; of these,>800,000 have end-stage renal disease requiring chronic dialysis or a kidney transplant to survive. Despite efforts to increase the donor kidney supply, approximately 100,000 people are registered on the kidney transplant wait-list with no measurable decrease over the past 2 decades. The outcomes of kidney transplantation are significantly better than for chronic dialysis: kidney transplant recipients have lower rates of mortality and cardiovascular events and better quality of life, but wait-list time matters. Time on dialysis waiting for a deceased-donor kidney is a strong independent risk factor for outcomes after a kidney transplant. Deceased-donor recipients with wait-list times on dialysis of<6 months have graft survival rates equivalent to living-donor recipients with waitlist times on dialysis of>2 years. In 2021,>12,000 people had been on the kidney transplant waitlist for ≥5 years. As the gap between the demand for and availability of donor kidneys for allotransplantation continues to widen, alternative strategies are needed to provide a stable, sufficient, and timely supply. A strategy that is gaining momentum toward clinical application is pig-to-human kidney xenotransplantation. This report summarizes the proceedings of a meeting convened on April 11-12, 2022, by the National Kidney Foundation to review and assess the state of pig-to-human kidney xenotransplantation as a potential cure for end-stage renal disease.
引用
- Adams AB, Blumberg EA, Gill JS, et al. Enhancing Kidney Transplantation and the Role of Xenografts: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2024. PMID: 38452918. doi:10.1053/j.ajkd.2023.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。